BCOP 2019 Self-Study Online Module Release II
BCOP Self-Study Online Modules - both releases will cover topics from all the BCOP domains and multiple hematology/oncology patient populations, and feature recent articles from primary oncology literature. BCOP Self-Study Modules are on-demand and allow you to review at your convenience.
Each module will include access to articles, pre-assessment questions, patient cases and the BCOP posttest. You may choose to complete all or select individual modules, receiving BCOP credit for each completed module which achieves a passing score.
Case study questions will count towards the overall test score for the BCOP credit. Your results in the case studies and the posttest questions will determine your total score which still must meet the 75% threshold for passing to earn BCOP credit.
Your purchase of Self-Study Release II includes 3 modules and offers up to 7.5 BCOP/ACPE credits.
Module 5: Chronic Graft-versus-Host Disease (2.5 BCOP/ACPE)
Module 6: Adolescent and Young Adult (AYA) (2.5 BCOP/ACPE)
Module 7: Pharmacy Accreditation (2.5 BCOP/ACPE)
HOPA Member Price: $165
Non-Member Price: $225
2019 BCOP Self-Study Online Module – Release II is also a part of both the 2019 BCOP Program Bundle and BCOP Self-Study Online Module Bundle. If you’ve already purchased the 2019 BCOP Program Bundle or BCOP Self-Study Online Module Bundle, you can access your Self-Study Modules in My Education Library.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by August 31, 2022.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form, case-study and post-test, with a combined passing grade of 75% or greater is achieved. Tests must be completed by February 28, 2020.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Module 5: Chronic Graft-versus-Host Disease
Description: Chronic graft-versus-host disease (cGVHD) is a major complication following allogeneic hematopoeitic stem cell transplantation which can significantly impact patients’ quality of life. Systemic corticosteroids are considered first-line therapy but often associated with inadequate response and a host of side-effects. Evidence-based, consensus guidelines are lacking in terms of the best approach to treating patients with steroid-refractory cGVHD. This self-study module aims to provide information on new approaches to treating steroid-refractory cGVHD. This module will highlight three articles outlining the only FDA approved drug for cGVHD, ibrutinib, new data on ruxolitinib and a cost-efficacy comparison of agents currently used in the management of cGVHD. Upon completion, the audience should gain a better understanding of second-line treatment options for patients experiencing cGVHD including mechanisms of action, monitoring, counseling, and side-effect management utilizing these therapies.Learning Objectives
- Review the pathophysiology of cGVHD including how it relates to novel treatment options
- Summarize the data from clinical trials on the use of ibrutinib and ongoing trials with ruxolitinib in the treatment of cGVHD
- Describe the role of ibrutinib and ruxolitinib in the treatment of steroid-refractory cGVHD
- Explain the cost-effectiveness of various therapies used in the treatment of steroid-refractory cGVHD
Speaker: Robert S. Mancini, PharmD BCOP
Disclosure:Takeda Oncology – SP – H
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-073-H04-P.
Activity Type: Application
Module 6: Adolescent and Young Adult (AYA) Oncology: Reproductive Health in Survivors
Description: The adolescent and young adult (AYA) oncology self-study will focus on reproductive health in survivors as one of many late endocrine effects of cancer treatment. This self-study will review recent articles that characterize late endocrine effects in AYA cancer survivors and provide an in-depth review of the impact of cancer treatment on male and female reproductive health. This module will also explore the role of hormone replacement therapy in optimizing reproductive health outcomes in AYA cancer survivors.
- Predict the types of endocrine late effects of cancer and cancer treatment in AYA survivors
- Identify cancer-related factors that affect future reproductive health and fertility in male and female AYA survivors
- Interpret the role of hormone replacement therapy in optimizing the reproductive health of male and female AYA survivors
Speaker: Jocelyn Mohs, PharmD BCOP
Disclosure: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-075-H04-P.
Activity Type: Application
Module 7: Pharmacy Accreditation
Description:Expanded use of specialty pharmacy products has added to the complexity of the US Healthcare System. While not specific to treatment of cancer, specialty pharmaceuticals make up a growing number of oncology products, particularly oral oncolytics. With the growing utilization of specialty pharmacy products, interactions between specialty pharmacies, ambulatory care clinics, hospitals, and manufacturers are becoming more common. This self-study module will review relevant articles chronicling development and implementation of specialty pharmacy programs, as well as specific articles describing specialty pharmacy experiences in malignant hematology and oncology populations.
- Analyze initial steps needed to implement a specialty pharmacy.
- Explore best practices related to patient-centered specialty pharmacy practices
- Summarize key processes related to initiation, monitoring and follow-up of oncology specialty pharmaceuticals.
Speaker:Matthew Eckley, PharmD BCOP BCPS
Disclosures: Takeda Oncology – E – S, ST, EQ
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-074-H04-P.
Activity Type: Application